Synageva BioPharma is focused on the development of biopharmaceuticals that address the
needs of a global patient population in multiple areas, including oncology, autoimmune
diseases and genetic diseases.
SynagevaTM has created sustainable value through its robust and cost-effective
protein expression technology, AESTM. We have generated a diverse pipeline
of follow-on products as well as next-generation products that may exhibit superior efficacy and
safety profiles. In addition we have targeted research programs focused on novel products for areas of high unmet medical need.
